Risk Factors for Treatment Failure in Women With Detrusor Overactivity Receiving Combined Pharmacotherapy

Mackay Memorial Hospital

Status: Completed

Conditions: Overactive Bladder

Treatments: Drug: Combined pharmacotherapy

Study type: Observational

Funder types: Other

Identifiers

NCT07337252

22MMHIS039e-4

Details and patient eligibility

About

This study evaluated the outcomes of women with detrusor overactivity treated with combined pharmacotherapy to identify risk factors for treatment failure.

Enrollment: 61 patients

Sex: Female

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with detrusor overactivity which defined as a urodynamic observation characterized by involuntary detrusor contractions during the filling phase. Those who were refractory to monotherapy with either anticholinergics or β3-agonist medication for at least 1 month.

Exclusion criteria

• Neurological conditions or spinal cord injury, which could affect urologic function
• Advanced pelvic organ prolapse (pelvic organ prolapse quantification system stage II or above)
• Active urinary tract infection
• Contraindications to taking anticholinergic and β3-agonist medications

Trial design

61 participants in 1 patient group

Women with urodynamic DO refractory to combined pharmacotherapy

Description:

We enrolled women with refractory detrusor overactivity, defined as ongoing symptoms after at least 1 month of treatment with either an anticholinergic or a β3-agonist. Eligible women received combined pharmacotherapy with oral solifenacin 5 mg and mirabegron 25 mg once daily for 12 weeks.

Treatment:

Drug: Combined pharmacotherapy